Alice Chambers |
Microsoft and 1910 Genetics have signed a five-year commercial agreement to improve research and development (R&D) productivity around the world through artificial intelligence.
1910 Genetics is an AI-native biotechnology company that aims to overcome data scarcity issues in the pharmaceutical industry, enhance testing operations with AI, and support modality-agnostic drug discovery.
The partnership will combine data from 1910 Genetic’s wet laboratory with Microsoft Azure Quantum Elements, launched in June 2023 to power AI models for chemistry-related work, to help pharmaceutical and R&D teams develop AI-driven We support the transition to drug discovery.
The companies also plan to use Azure systems to train multimodal AI models.
1910 Genetics wet lab data helps the pharmaceutical industry transition to AI-driven drug discovery (Image credit: Microsoft)
“AI provides an opportunity to reduce the time from observation to discovery,” Zulfi Alam, corporate vice president of Azure Quantum at Microsoft, said in a Microsoft blog. “AI for scientific discovery enables humans with AI to rapidly digest centuries of scientific knowledge, identify patterns, observe, hypothesize, and predict outcomes while reducing the need for experimentation.” It is characterized by an expansion of intelligence.”
